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Neuronal microtubules are stabilized by two 
calmodulin-regulated microtubule 
associated proteins, E-STOP and N-STOP, 
whose suppression in mice induces severe 
synaptic and behavioral deficits. Here we 
show that mature neurons also contain a 21 
kD STOP-like protein, SL21, which shares 
calmodulin-binding and microtubule-
stabilizing homology domains with STOP 
proteins. Accordingly, in different 
biochemical or cellular assays, SL21 has 
calmodulin-binding and microtubule-
stabilizing activity. However, in cultured 
hippocampal neurons, SL21 antibodies 
principally stain the somatic Golgi and 
punctate Golgi material in neurites. In 
cycling cells, transfected SL21 decorates 
microtubules when expressed at high levels 
but is otherwise principally visible at the 
Golgi. The Golgi targeting of SL21 depends 
on the presence of cysteine residues located 
within the SL21 N-terminal domain, 
suggesting that Golgi targeting may require 
SL21 palmitoylation. Accordingly we find 
that SL21 is palmitoylated in vivo. N-STOP 
and E-STOP, which contain the Golgi 
targeting sequences present in SL21, also 
display distinct Golgi staining when 
expressed at low level in cycling cells. Thus 
neuronal proteins of the STOP family have 
capacity to associate with Golgi material, 
which could be important for STOP 
synaptic functions. 
 
Neurons contain abundant sub-
populations of stable microtubules that resist 
depolymerizing conditions such as exposure to 
the cold. This property is due to microtubule 
association with E-and N-STOP, two neuronal 
calmodulin-binding and calmodulin-regulated 
proteins (1-3). STOP proteins are important for 
synaptic function and STOP null mice present 
defects in both short- and long-term synaptic 
plasticity, associated with severe behavioral 
and neurotransmitter deficits (1,4). At the 
ultrastructural level, the main signature of 
STOP suppression is a dramatic depletion of 
synaptic vesicle pools in glutamatergic 
neurons. 
E- and N-STOP arise from mRNA 
splicing of a single gene (5). These STOP 
proteins contain modular motifs (3) that are 
 
Golgi localization of STOP 2
either bi-functional (calmodulin-binding and 
microtubule-stabilizing sequences; Mc and Mn 
modules), or are comprised of calmodulin-
binding sequences, unrelated to microtubule-
stabilizing sequences. 
We have previously described a number 
of STOP splicing variants, which are 
principally present in non-neuronal cells (6), 
but for a long time, STOPs seemed to be 
unique with no STOP-related proteins. 
However, strong evidence for a 21 kD STOP-
like protein (SL21) has arisen from database 
searches (3). SL21 contains a 35 aa N-terminal 
stretch which shares 83% homology with the 
N-terminal part of E- or N-STOP, and contains 
a calmodulin-binding motif. A second domain 
of SL21, spanning 24 aa, shares 71% 
homology with a microtubule-stabilizing Mn 
module of E- and N-STOP (3,7). 
Here, we demonstrate that SL21 is a neuronal 
protein, strictly expressed in the post-natal 
brain. We show that SL21 has microtubule-
stabilizing activity similar to E- and N-STOP. 
However, surprisingly, endogenous SL21 co-
localizes with the somatic Golgi apparatus and 
with dendritic Golgi structures in cultured 
hippocampal neurons. We show that the N-
terminal part of SL21 comprises a Golgi-
targeting sequence with critical cysteine 
residues, which sustain SL21 palmitoylation. 
The SL21 Golgi targeting sequence is also 
present and functional in E-and N-STOP. 
In light of studies indicating that the presence 
of Golgi material in neurites and synapses may 
be important for synaptic plasticity (8), a Golgi 
interactions with STOP could be important for 
STOP function in synapses. 
 
EXPERIMENTAL PROCEDURES 
Sequence analysis - Mouse N-STOP protein 
sequence (GenBank Accession number 
CAA75930) was submitted to the BLAST 
program 
(http://www.ncbi.nlm.nih.gov/BLAST/) to 
identify STOP-related proteins. GenBank 
Accession numbers of these proteins were 
CAA63762 for rat N-STOP, NP_149052 for 
human N-STOP, XP_508647 for chimpanzee 
N-STOP, XP_596995 for cow N-STOP, 
NP_941001 for mouse SL21, XP_344040 for 
rat SL21, AAH06434 for human SL21, 
XP_516902 for chimpanzee SL21, and 
XP_608343 for cow SL21. Protein sequence 
alignments were performed using the multiple 
alignment software Clustal W (9). 
Plasmid constructs - On the basis of the mouse 
SL21 cDNA sequence (GenBank Accession 
number BY727771), the entire open reading 
frame of mouse SL21 was amplified by PCR. 
We used Mouse Brain Marathon Ready cDNA 
(BD Biosciences) and the Advantage-GC2 
Polymerase Mix (BD Biosciences), with 
primers containing Bgl II extensions. The 
resulting PCR product was first cloned into 
pCR2.1-TOPO (Invitrogen). For expression in 
mammalian cells, the complete coding 
sequence was cloned in pSG5 vector 
(Stratagene) and in pcDNA3.1(-)/Myc-His-A 
vector (Invitrogen) to be fused with the myc 
epitope DNA. For production and purification 
in bacterial system, the complete coding 
sequence was cloned into pGex-4T3 vector 
(Amersham Biosciences), to fuse GST after the 
last amino acids (aa) of SL21. The two SL21 
deletion mutants were obtained by PCR, and 
correspond to Met + aa 35-191 (SL21∆2-34) 
and to aa 1-122 + aa 146-191 (SL21∆Mn3), 
according to the numbering of mouse SL21 
protein. The replacement of Cys5, Cys10 and 
Cys11 by glycine residues (SL21-
C(5/10/11)G) was obtained by PCR, with a 
degenerate 5’- oligonucleotide (5’-AgA TCT 
ATg gCg Tgg CCC ggC ATC AgC Cgg CTA 
ggC ggC CTg gCC –3’). The STOP coding 
sequence of LNt∆Mn1Mn2, corresponding to 
aa 1-123 + Ala + aa 139-161 + Ile-Gln + aa 
175-225 according to the numbering of rat N-
STOP, was amplified by PCR and then 
subcloned into the pcDNA3.1(-)/Myc-His-A 
vector to be fused with the myc epitope DNA. 
N-STOP plasmid is described in (2,10). The 
STOP coding sequence of N-STOP∆2-19, 
corresponding to Met + aa 20-952 according to 
the numbering of rat N-STOP, was amplified 
by PCR and then subcloned into the pSG5 
vector. All the SL21 and STOP constructs 
were confirmed by DNA sequencing. 
Production of SL21-GST - Plasmid pGex-4T3 
containing SL21 cDNA was transformed in 
One Shot BL21 (DEA3) Star cells (Invitrogen) 
according to the manufacturer’s instructions. 
Transformed cells expressing SL21-GST were 
grown at 37° C to an OD600 of 0.6, and induced 
with 0.5 mM IPTG for 3 h at 37° C. Cells were 
pelleted and resuspended in PBS containing 
1% Triton X-100, protease inhibitors 
(Complete Cocktail tablets, Roche) and 
sonicated for 1.5 min before centrifugation 
(17,000 g for 10 min). The supernatant was 
incubated with glutathione-Sepharose beads. 
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These beads were placed in columns and 
successively washed with PBS containing 1% 
Triton X-100, then with PBS and finally with 
50 mM Tris, pH 8.0. The GST fusion proteins 
were eluted with 10 mM glutathione in 50 mM 
Tris (pH 8.0). 
Western blot analysis - Tissues from mice 
were homogenized in a 100 mM K-Pipes, 1 
mM EGTA, and 1 mM MgCl2 buffer (pH 
6.65). The homogenates were centrifuged at 
200,000 g for 30 min at 4° C. Supernatants 
were then harvested and analyzed by 
SDS/PAGE (11). For immunoblotting, proteins 
were subsequently transferred onto 
nitrocellulose membranes and processed as 
previously described (12). 
Sedimentation of proteins with microtubules - 
All proteins were pre-clarified at 150,000 g for 
15 minutes in a TL-100 ultracentrifuge at 4°C 
prior start experiments. STOP proteins were 
purified as described in Pirollet et al (13). 
Microtubule-binding assay was performed as 
in Masson and Kreis (14) using taxol-stabilized 
microtubules (4 µM) as substrates and a 60% 
glycerol cushion. 
Assay of Calmodulin Binding to Immobilized 
Peptide - Immobilized peptide arrays 
corresponding to the human SL21 were 
produced according to (15) with an ABIMED 
ASP 222 automated SPOT robot. The protein 
sequence was subdivided into 15-mer peptides 
with an overlap of 12 aa. The peptides were 
synthesized spotwise as an array on a specially 
manufactured cellulose membrane (AIMS 
Scientific Products GmbH, Braunschweig, 
Germany). The peptides are permanently 
linked to the membrane through their carboxy-
terminal aa via a polyethylene glycol spacer. 
The synthesis procedure followed exactly that 
of (16). Overlay binding assay were performed 
as in (3), using [35S]-labeled calmodulin. 
Cell culture - Hippocampal cell cultures were 
prepared as previously described (17). Briefly, 
hippocampi brain tissue from E18.5 mice were 
removed and digested in 0.25% trypsin in 
Hepes-buffered Hanks' balanced salt solution 
(HBSS) at 37° C for 15 min. After manual 
dissociation, cells were plated at a 
concentration of 5,000–15,000 cells/cm2 on 
poly-L-lysine (Sigma) coated coverslips, in 
DMEM - 10% FBS. One hour after plating, the 
medium was changed to DMEM containing 
B27 and N2 supplement (Invitrogen). HeLa 
and NIH 3T3 cells were cultured in RPMI-
Glutamax or DMEM-Glutamax, respectively, 
supplement with 10% SVF and 1% 
penicillin/streptomycin (Invitrogen). 
Transient Transfection and Analysis of 
microtubule Stability - Exponentially growing 
HeLa or NIH 3T3 cells were transfected with 
the cDNAs described above, using FuGENE 6 
(Roche Diagnostics), according to the 
manufacturer’s instructions. Transfected cells 
were either directly processed for 
immunofluorescence or exposed to cold 
temperature (30 min on ice) or to nocodazole 
(20 µM for 30 min). Cells were then 
permeabilized in lysis buffer (30 mM Pipes, 1 
mM EGTA, 1 mM MgCl2, 10% glycerol, 0.1% 
Triton X-100, pH 6.75) for 1 min, and 
processed for immunofluorescence. 
Antibodies - Primary antibodies were: mAb 
against α-tubulin (TUB2.1) diluted to 1/100 
(Sigma); rat mAb against tyrosinated tubulin 
(YL1/2) diluted to 1/5,000 (18); mAb against 
GM130 diluted to 1/50 and against GS28 
diluted to 1/200 (BD Transduction 
Laboratories); rabbit polyclonal antibody 
against giantin (Covance) diluted to 1/2,000; 
rabbit polyclonal antibody 23C against STOP 
(2) diluted to 1/400. Rabbit polyclonal 
antibodies 3315, were raised against synthetic 
peptide FQVPEVRKFTPNPSAI, 
corresponding to aa 164-179 of mouse SL21 
(Eurogentec). Serum 3315 was affinity-
purified with the corresponding peptide and 
used diluted to 1/4,000 and to 1/400 for 
Western blot and immunofluorescence, 
respectively. 
Secondary antibodies were: anti GST 
peroxydase-coupled (Santa Cruz); anti-mouse 
Alexa 488- (Molecular probes) or Cy5-
coupled, anti-rabbit Cy3-coupled, and anti-rat 
Alexa 488-coupled (Jackson Immuno 
Research) antibodies. 
Immunofluorescence - Hippocampal neurons 
were then either permeabilized in OPT buffer 
(80 mM Pipes, pH 6.7, 1 mM EGTA, 1 mM 
MgCl2, 0.5% Triton X-100, 10% glycerol) at 
35°C for 2 min before fixation, or fixed 
directly for 10 min in methanol at -20°C. Cells 
were then incubated with primary antibodies 
for 45 min in PBS - Tween 0.5% and with 
secondary antibodies for 40 min. Cells were 
analyzed with a laser confocal microscope 
(TCS-SP2, Leica), or with an inverted 
microscope Axioscop 50 (Zeiss) controlled by 
Metaview (Universal Imaging, Downingtown, 
PA). Images were digitalized using a Coolsnap 
ES camera (Roper Scientific). 
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[3H]-Palmitate labeling and 
Immunoprecipitation - HeLa cells were either 
non transfected or transfected with SL21-myc 
or SL21 C(5/10/11)G-myc cDNAs. One day 
after transfection, cells were labeled for 3 h 
with 500 µCi [3H]-palmitic acid (Amersham). 
The radioactive palmitic acid was completely 
dried under nitrogen and resuspended in 12.5 
µl of DMSO and complemented with 1 ml of 
RPMI containing 0,5% de-fatted BSA (Sigma). 
Cells were washed and scraped with PBS. 
After centrifugation at 12,000 g for 2 min cells 
were lysed in IP buffer (50 mM Tris, 150 mM 
NaCl, 0,05% deoxycholate, 1% Triton X-100, 
10% glycerol, pH 8.0) in the presence of 
protease inhibitors (Complete Cocktail tablets, 
Roche) and 5 mM CaCl2. After centrifugation 
of the cell lysate at 12,000 g for 5 min at 4° C, 
the supernatant was supplement with 5 mM 
EGTA and incubated for 2 h at 4° C with 25 µl 
myc antibody (Santa Cruz biotech) pre-
incubated 2 hours at 4° C with 30 µl protein G-
sepharose (Amersham). After centrigugation at 
12,000 g for 2 min, immunoprecipitate were 
washed 5 times in IP buffer for 10 min at 4° C. 
Samples were separated by SDS-PAGE, and 
gels were fixed 30 min in 50% methanol - 10% 
acetic acid and treated 30 min with Amplify 
solution (Amersham), in order to improve the 
radioactive signal. The gels were dried and 
exposed on autoradiography films for 10 days 





STOP homology domains in SL21 – E- and N-
STOP contains two classes of bi-functional 
calmodulin-binding and stabilizing modules, 
Mc modules and Mn modules (Fig. 1A). E- 
and N-STOP also contains additional 
calmodulin-binding sequences unrelated to Mn 
or Mc modules (Fig. 1A). The first 35 aa of 
SL21 share 83% homology with the N-
terminal aa of E- and N-STOP which 
comprises, in STOPs, the functional 
calmodulin-binding motif called Cam1 (3). A 
second domain of SL21, spanning 24 aa, share 
71% homology with the E- and N-STOP 
bifunctional calmodulin-binding (Cam5) and 
microtubule-stabilizing Mn3 module (3). The 
homologous domains of N-STOP and SL21 are 
aligned figure 1B. 
Calmodulin-binding properties of SL21 – All 
the STOP calmodulin-binding sites including 
Cam1 and Cam5 were initially identified as 
calmodulin-binding motifs on N-STOP 
immobilized peptide arrays (3). A similar 
assay with SL21 peptides (Fig. 2A-B) showed 
that the STOP Cam1 and Cam5 homologous 
motifs of SL21 (SL-Cam1 and SL-Cam3, 
respectively), also bound [35S]-calmodulin 
(peaks 1 and 3, Fig. 2B-C), together with two 
other apparently weaker calmodulin-binding 
motifs, (SL-Cam2 and SL-Cam4, peaks 2 and 
4 respectively) (Fig. 2B-C). 
Calmodulin-binding motifs in N-STOP have 
been shown to bind to immobilized Ca2+-
calmodulin in vitro (3). Accordingly, 4 
independents experiments consistently showed 
that recombinant SL21-GST bound to 
calmodulin column, as illustrated in Fig. 2D. 
The binding was strictly dependent on the 
presence of calcium as shown by the release of 
SL21 from the calmodulin column by EGTA 
buffer (Fig. 2D) and by the non-binding of 
SL21 to calmodulin column in the absence of 
calcium (Fig. 2D). The binding of SL21-GST 
to calmodulin is mediated by SL21 as GST 
alone was unable to bind to immobilized 
calmodulin (data not shown). Thus, SL21 
behaves as a bona fide calmodulin-binding 
protein in vitro. 
Microtubule-binding and stabilizing activity of 
SL21 – In E- and N-STOP, Mn modules 
mediate STOP association with microtubules 
with resulting inhibition of microtubule 
depolymerization upon exposure to the cold or 
to nocodazole (3). In agreement with the 
presence of a Mn module sequence in SL21, 
SL21 co-sedimented with taxol-stabilized 
microtubules in standard microtubule-binding 
assays, while remaining in the soluble fraction 
in the absence of microtubules (Fig. 3A). In the 
same microtubule-binding assay, N-STOP co-
sedimented with microtubules whereas GST 
remained in the supernatant. In quantitative 
experiments, various amount of tubulin were 
polymerized and then incubated with GST-
SL21 at 2 µM. Then, polymerized tubulin was 
pelleted and SL21 content was analyzed on 
immunoblots, in both supernatants and pellets 
(Figure 3B). The concentrations of tubulin at 
which approximately half of SL21 co-
sedimented with microtubules was circa 5 µM 
(Figure 3B). In additional experiments, GST-
SL21 at various concentrations was mixed with 
polymerized tubulin (10 µM). Then, 
microtubules were pelleted and SL21 content 
was analyzed on immunoblots, in both 
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supernatants and pellets (Figure 3C). In this 
experiment, SL21 at 4 µM was found both in 
the supernatant and in the pellet whereas at 
concentration of SL21, ranging from 2 µM to 
0.5 µM, SL21 is only found associated with 
microtubules. Altogether these results showed 
that SL21 behaved as a microtubule-binding 
protein in vitro.  
We used HeLa cells for microtubule-binding 
and -stabilization tests in vivo. HeLa cells are 
devoid of STOP, of SL21 and of cold-stable or 
nocodazole-resistant microtubules (Fig. 3D). 
When transfected in HeLa cells, a SL21 mutant 
(SL21∆2-34), lacking the N-terminal domain 
and containing the Mn module, decorated 
cytoplasmic microtubules and induced both 
microtubule cold stability and microtubule 
resistance to nocodazole (Fig. 3E), compatible 
with functionality of the Mn module of SL21 
in vivo. As shown below, the behavior of the 
full-length SL21 in cells was more complex 
than the mutant lacking the N-terminal domain 
(SL21∆2-34), due to interfering influence of 
the N-terminal sequence. 
Tissue distribution and cellular localization of 
endogenous SL21 - We used Western blot 
analysis of mouse tissues with SL21 
polyclonal antibody 3315 to determine the 
distribution pattern of SL21. SL21 was 
only detected in brain tissue (Fig. 4A). In 
tissue extracts from new-born brain, SL21 
expression was low at P0 and increased 
after P10 (Fig 4A). We then tested the 
presence of SL21 in various neuronal cell 
lines, using both immunoblot analysis and 
immunofluorescence microscopy. SL21 
was not detected in neuronal cell lines 
(N2A, PC12 and NG108) whether cultured 
in the presence or absence of NGF (data 
not shown). In contrast, SL21 was present in 
neurons, in primary cultures, being absent from 
glial cells (data not shown). Interestingly, in 
differentiating hippocampal cultured neurons, 
SL21 antibodies principally stained a juxta-
nuclear structure corresponding to the somatic 
Golgi apparatus, as demonstrated by co-
localization with the cis-Golgi marker GS28 
(Fig. 4B). At late stages of neuronal 
differentiation in vitro (16 DIV), in addition to 
the somatic Golgi, both SL21 and GS28 
antibodies yielded a punctuated staining of 
neuritic extensions (Fig. 4B), corresponding to 
staining of neurite vesicular Golgi (19). A 
distinct microtubule staining was also visible 
after triton-soluble protein extraction (Figure 
4D). Disruption of the somatic Golgi with 
Brefeldine A treatment, in differentiated 
neurons, induced a dramatic re-distribution of 
SL21 and GS28 stainings, which both became 
diffuse (Fig. 4C). These results indicate that 
SL21 is specifically expressed in differentiated 
neuronal cells and that it localizes to 
microtubules, to the somatic Golgi and to 
Golgi material traveling throughout neurites. 
 
Dual localization of transfected SL21 in NIH 
3T3 cells: microtubule- and Golgi-targeting 
sequences in SL21- We used NIH 3T3 cells 
which have a well organized somatic Golgi 
and SL21 mutants for further analysis of SL21 
localization and domain structure. When 
expressed in NIH 3T3 cells, the apparent 
localization of SL21 varied as a function of its 
expression level. At low levels of expression, 
SL21 was principally detectable on the Golgi 
(Fig. 5A). At higher levels of expression, there 
was also distinct SL21 staining of cytoplasmic 
microtubules (Fig. 5B). The deletion of the Mn 
module (SL21∆Mn) suppressed the 
microtubule association of SL21, at all 
expression levels, while preserving Golgi 
localization (Fig. 5C). Conversely, at all levels 
of expression in NIH 3T3 cells, a deletion 
mutant of SL21 lacking 34 N-terminal aa 
(SL21∆2-34), associated with microtubules 
(data not shown) as in the case of HeLa cells 
(Fig. 3F) with no Golgi localization. In 
additional microtubule stabilization assays in 
HeLa cells, we found that native SL21 
expressed at high levels and the SL21∆2-34 
deletion mutant had microtubule stabilizing 
activity, whereas the SL21 mutant SL21∆Mn, 
which shows exclusive Golgi localization, had 
no detectable effect on microtubule stability 
(not shown).  
Altogether, these results indicate that the 
targeting of SL21 to microtubules depends on 
the presence of the Mn module and that SL21 
comprises a Golgi-targeting sequence located 
in the N-terminal domain of the protein. 
 
Palmitoylation of SL21 - Palmitoylation is 
often required for protein association with 
membranes and has been previously observed 
in neuronal proteins associated with tubulin 
and with the Golgi such as SCG10 (20). 
Palmitoylation occurs at cysteine residues 
surrounded with basic residues (21). Mouse 
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SL21 contains 3 cysteine residues, all located 
in the Golgi-targeting domain (positions 5, 10 
and 11) and surrounded by basic residues (Fig. 
6A). To assess whether these cysteines were 
involved in the localization of SL21 to the 
Golgi apparatus, we produced cDNAs 
encoding SL21 mutants in which Cys5, Cys10 
and Cys11 were replaced by glycine residues. 
These constructs were then transfected in NIH 
3T3 cells, and the Golgi localization of the 
mutants was examined. In contrast to SL21, 
which localizes to the Golgi, the SL21 mutant 
where all the three cysteine residues were 
replaced (SL21-C(5/10/11)G) did not localize 
to the Golgi, but co-localized with 
microtubules (Fig. 5D). These results indicate 
a requirement of SL21 N-terminal Cys5, 
Cys10, Cys11 for proper localization of SL21 
to Golgi apparatus. To test SL21 
palmitoylation directly, HeLa cells were 
incubated with [3H]-palmitate, with or without 
prior transfection with SL21-myc or SL21-
C(5/10/11)G-myc cDNA. Then, SL21-myc and 
SL21-C(5/10/11)G-myc were 
immunoprecipitated from cell extracts and the 
immunoprecipitated proteins were analyzed 
both by Western blot, using SL21 polyclonal 
antibody 3315, and by autoradiography (Fig. 
5E). As shown in Fig. 5E, SL21 incorporated 
3H, whereas SL21-C(5/10/11)G mutant did 
not, demonstrating that SL21 is indeed 
palmitoylated in cells and showing the crucial 
role of Cys5, Cys10 and Cys 11 in this process. 
These results were obtained for 3 independent 
experiments and similar results were observed 
when using SL21-GFP instead of SL21-myc 
(data not shown).  
Golgi targeting of N-STOP - The N-terminal 
Golgi-targeting sequence of SL21, which is 
conserved among mammals, is also present at 
the N-terminus of N-STOP (Fig. 6A). 
Accordingly, a 225 aa N-terminal fragment of 
N-STOP containing the Golgi-targeting 
sequence and deleted for microtubule binding 
modules, Mn1 and Mn2 (LNt∆Mn1Mn2) was 
uniformly addressed to the Golgi when 
transfected in NIH3T3 cells (Fig 6B). Despite 
the presence of such a functional Golgi-
targeting sequence at their N-terminus, E- and 
N-STOP have not been detected at the Golgi in 
previous studies, this could be due either to a 
dominant influence of the STOP microtubule-
targeting sequences (Mn and Mc modules) or 
to unfavorable experimental procedures. To 
test these possibilities, we re-examined N-
STOP localization in various cell types and 
conditions. In neurons, STOP antibody yielded 
a bright staining of the whole cell body, 
making a possible STOP localization at the 
Golgi hard to detect (2).Interestingly, in NIH 
3T3 cells, transfected N-STOP staining was 
principally detectable at the Golgi  at low 
levels of expression (Fig. 6C) both Golgi and 
microtubule staining being present at high 
expression levels (Fig. 6D). Moreover, a 
transfected N-STOP mutant (N-STOP∆2-19), 
lacking the Golgi targeting sequence, failed to 
associate with the Golgi (Fig. 6E). Altogether, 
these results indicate that the ability to localize 
to Golgi material is a shared property of STOP 
and STOP-like proteins, due to the presence of 





In this study, SL21 and neuronal STOPs (E-
STOP and N-STOP) emerge as a class of 
microtubule-binding and calmodulin-binding 
proteins, sharing both a Golgi-targeting 
sequence and microtubule-stabilizing modules. 
We note that the STOP Golgi-targeting 
sequence is only present in E-and N-STOP 
being absent from all the other known STOP 
variants (6). As E- and N-STOP, SL21 is 
specific of neurons and both SL21 and N-
STOP are expressed only in the post-natal 
brain. Despite such similarities in structure and 
activity, there is an apparent difference in the 
cellular distribution of endogenous SL21 and 
N-STOP, SL21 being preferentially associated 
with the somatic Golgi and N-STOP with 
microtubules, in neurons. However both SL21 
and N-STOP are principally detected at the 
Golgi when expressed at low levels in cells, 
whereas being also visible on cytoplasmic 
microtubules at high levels of expression. The 
apparent differences between endogenous 
SL21 and N-STOP localization in neurons may 
thus reflect differences in expression levels, N-
STOP probably being much more abundant 
than SL21. Superimposed cell regulations may 
also affect SL21 or STOP localization. The 
Golgi targeting of SL21 and of STOP most 
likely depend on palmitoylation, which is a 
regulated and reversible covalent protein 
modification (22,23). Also, the microtubule-
binding activity of Mn modules can be 
inhibited by calmodulin (24) and, in the case of 
STOP, through phosphorylation, opening the 
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possibility of a protein shift from microtubules 
to other cell compartments (25).  
Why should neurons contain specific 
microtubule-associated proteins with Golgi-
binding activity? The somatic Golgi in neurons 
has an organization similar to that observed in 
non-neuronal cells, although the Golgi orients 
toward the longest dendrite and this Golgi 
polarity precedes the asymmetric dendrite 
growth (26). Additionally there is evidence for 
the presence of Golgi material along neurites. 
Previous ultrastructural studies have reported 
membranes analogous to Golgi cisternae 
within the spines of distal dendrites (27,28). 
Moreover many neurons possess both somatic 
Golgi and discrete, discontinuous Golgi-type 
structures (“Golgi outposts”) located far into 
the dendrites. These “Golgi outposts” are 
mobiles structures and are positioned to serve 
particular dendrites regions or sets of synapses, 
where they may be important for synaptic 
plasticity (8,19). Ability of Golgi binding may 
therefore be important for the function of N-
STOP in synaptic plasticity (1). Additionally, 
palmitoylation may allow STOP interaction 
with vesicular or membrane material other than 
the Golgi (29) and may thereby be central for 
the dramatic effects of STOP suppression on 
the synaptic vesicle density (1). Moreover, 
palmitoylation has specifically been shown to 
play a role in neuronal protein trafficking, and 
in the clustering of receptors and the associated 
scaffolding proteins at synapses (29,30). 
According to the present study, SL21 and 
STOP have extensively overlapping activities. 
Yet, STOP suppression is not compensated by 
SL21 in STOP deficient mice and we have not 
detected any obvious modification in SL21 
expression (data not shown). What is the utility 
of SL21 in the presence of STOP? We have 
performed SL21 siRNA experiments in 
hippocampal neurons, with inconclusive 
results (data not shown). It is likely that, as for 
N-STOP, SL21 function will be revealed by its 
suppression in whole animals, where complex 
aspects of synaptic function can be 
investigated. STOP or SL21 null animals may 
offer exciting models to test a role of the Golgi 
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Figure 1: STOPs and SL21 conserved domains 
(A) Schematic representations of mouse N-STOP, E-STOP and SL21. Calmodulin-binding sites 
(asterisks) and microtubule-stabilizing modules Mn and Mc (green and dark gray, respectively) are 
represented on E- and N-STOP. Calmodulin-binding sites Cam1 and Cam5 and aa numbering are 
indicated. N-STOP C-terminal repeats, absent in E-STOP, are in light gray. The common N-terminal 
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domain is in yellow. (B) Alignment of SL21 and STOP conserved N-terminal sequences (top) and of 
conserved Mn module (bottom). Conserved amino acids are shown in red. The N-STOP calmodulin-
binding sequences Cam1 and Cam5 are underlined. Numbers correspond to aa position in mouse SL21 
and N-STOP proteins. 
 
Figure 2: Calmodulin-binding properties of SL21 
Identification of SL21 calmodulin-binding motifs using immobilized peptide array and calmodulin-
agarose binding of SL21. (A) [35S]-labeled calmodulin overlay of a membrane containing SL21 
immobilized peptide array. The overlapping peptides (15-mers, with an orverlap of 12 aa) were numbered 
from the amino-terminal to the carboxyl-terminal residues of SL21. Numbers correspond to the first 
peptide of each line. Four peptide clusters interacting with [35S]-labeled calmodulin were detected by 
autoradiography. (B) Quantitative analysis of [35S]-calmodulin binding to mouse SL21 peptides. The 
radioactive signals observed in A were quantified using phosphorimager and results were plotted. Signal 
values are in arbitrary units (A. U.). The four peaks of maximum radioactivity signal correspond to SL21 
aa 6-20 (peak 1), aa 87-101 (peak 2) aa 141-155 (peak 3) aa 177-191 (peak 4). (C) Calmodulin-binding 
sites SLCam1 to SLCam4, corresponding to peaks 1 to 4 in (B), are reported on the schematic 
representation of SL21 (asterisks) and their sequences are given. (D) Binding of SL21-GST to 
immobilized calmodulin-agarose. Recombinant SL21-GST was produced in bacteria and loaded onto a 
calmodulin-agarose column in the presence (left panel) or in the absence (right panel) of 1 mM Ca2+. The 
column was washed and proteins were subsequently eluted with EGTA-containing buffer. Equal aliquots 
of the loaded sample (L), flow-through fraction (F), and EGTA elution fractions (1-5) were analyzed for 
SL21-GST content using SDS-PAGE gel electrophoresis followed by immunoblot analysis with SL21 
polyclonal antibody 3315. 
 
Figure 3: Microtubule-binding and -stabilizing activity of SL21 
(A-C) Microtubules co-sedimentation assays. (A) Co sedimentation of SL21-GST, N-STOP and GST with 
taxol-stabilized microtubules (10µM). SL21-GST, N-STOP and GST were incubated with (+) or without 
(-) taxol-stabilized microtubules (MT). The samples were then sedimented through a 60% glycerol 
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cushion. The supernatants (S) and the pellets (P) were analyzed for SL21, N-STOP and GST content by 
immunoblot using SL21 polyclonal antibody 3315, N-STOP polyclonal antibody 23C and GST antibody, 
respectively. (B) Various amount of tubulin (3 µM, 13 µM, 26µM and 40 µM) were polymerized, mixed 
with GST-SL21 (2 µM) and centrifuged. Equal amounts of supernatant and pellets were separated by SDS 
PAGE and were stained with Commassie blue, showing no detectable amount of tubulin in the 
supernatant. The supernatants (S) and the pellets (P) were analyzed for SL21 content by immunoblot using 
SL21 polyclonal antibody 3315. (C) Various amount of SL21 (4 µM, 2 µM, 1 µM and 0.5 µM) were 
incubated with polymerized tubulin (10µM). After centrifugation, equal amount of supernatants and 
pellets were separated by SDS PAGE and analyzed for SL21 content by immunoblot using SL21 
polyclonal antibody 3315. 
(D-E) Microtubules stability in cells. HeLa cells were either non-transfected (D) or transfected with a 
cDNA encoding SL21 mutant lacking the N-terminal domain and containing the Mn module (SL21∆2-34) 
(E). After 24 h, cells were either maintained at 37° C, exposed to 4° C, or treated with 20µM nocodazole 
for 30 min. Cells were then double-stained for microtubules (α-tubulin mAb) and for SL21∆2-34 (SL21 
polyclonal antibody 3315). Bar, 10 µm. 
 
Figure 4: Tissue distribution and cellular localization of SL21. 
(A) Immunoblot analysis of adult mouse tissues and post-natal brain (P0-P10) using SL21 polyclonal 
antibody 3315. (B) Distribution of SL21 protein in cultured mouse hippocampal neurons, after 9 or 16 
days of differentiation in vitro (DIV). Double staining of SL21 and Golgi was performed using SL21 
polyclonal antibody 3315 and GS28 monoclonal antibody. Images were acquired using laser confocal 
microscopy. Bar, 40 µm. (C) Golgi-dependent localization of SL21. Hippocampal neurons, after 9 DIV 
were either untreated or treated with Brefeldine A (10 µg/ml) for 1 h or 4 h. SL21 and Golgi stainings and 
image acquisition were as in (B). (D) Distribution of SL21 protein in cultured mouse hippocampal 
neurons (9 DIV) after permeabilisation of the cells. Triple staining of SL21, microtubules and Golgi was 
performed using SL21 polyclonal antibody 3315, anti α tubulin and GS28 monoclonal antibodies. After 
triton-soluble protein extraction, SL21 staining can be observed on microtubule network. Bar, 8 µm. 
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Figure 5: Golgi versus microtubule localization of SL21 and SL21 mutants in transfected cells. 
(A-B) NIH 3T3 cells transfected with a cDNA encoding the complete form of SL21. Double 
immunofluorescence analysis was performed using an SL21 polyclonal antibody 3315 and either GM130 
mAb for Golgi staining (A) or α-tubulin mAb for microtubule staining (B). Cells were expressing either 
low (A) or high levels (B) of SL21. All the image acquisitions and merges were performed using laser 
confocal microscopy. (C) NIH 3T3 cells transfected with a cDNA encoding SL21∆Mn and double-stained 
for Golgi (GM130 mAb) and for SL21∆Mn (SL21 polyclonal antibody 3315). (D) NIH 3T3 cells 
transfected with a cDNA encoding SL21-C(5/10/11)G and triple stained for microtubules (YL1/2 mAb), 
Golgi (GM130 mAb) and SL21 (SL21 polyclonal antibody 3315). Bar, 20 µm (A, C, D) and 16 µm (B). 
Schematic representations of proteins are as in Fig. 1A. (E) Incorporation of [3H]-palmitate into SL21-myc 
and SL21-C(5/10/11)G-myc mutant. HeLa cells overexpressing SL21-myc or SL21-C(5/10/11)G-myc 
mutant were incubated with [3H]-palmitate, and proteins were immunoprecipited with anti myc antibody. 
Immunoprecipited proteins were separated by SDS-PAGE and subject to autoradiography or Western blot 
using SL21 polyclonal antibody 3315. Untransfected cells were used as control. 
 
Fig. 6. Golgi-targeting of the N-terminal domain of N-STOP. 
(A) Alignment of the N-terminal domains of STOP and SL21 proteins from various species, as indicated. 
Amino acids conserved in N-STOP and SL21 are boxed in black. Among the strongly conserved aa, the 
cysteine residues 5, 10 and 11 are boxed in red. Numbers correspond to aa position. (B) NIH 3T3 cells 
transfected with a cDNA encoding STOP fragment LNt∆Mn1Mn2-myc and double-stained for Golgi 
(Giantin polyclonal antibody) and for LNt∆Mn1Mn2 (myc mAb). (C-D) NIH 3T3 cells transfected with a 
cDNA encoding N-STOP and expressing either low (C) or high levels (D) of N-STOP. Cells were double-
stained for STOP (polyclonal antibody 23C) and either for Golgi (GM130 mAb) or microtubule (α-tubulin 
mAb). (E) NIH 3T3 cells transfected with a cDNA encoding N-STOP∆2-19 and double-stained for STOP 
(polyclonal antibody 23C) and for microtubule (α-tubulin mAb). Schematic representations of proteins are 
as in Fig. 1A. Bar, 20 µm. 
 
 






